Claiborne Cary J 4
4 · ADIAL PHARMACEUTICALS, INC. · Filed Jun 2, 2025
Insider Transaction Report
Form 4
Claiborne Cary J
DirectorChief Executive Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-05-29+138,000→ 138,000 totalExercise: $0.69Exp: 2035-05-28→ Common Stock (138,000 underlying)
Footnotes (1)
- [F1]The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.